Company continues to supply high-quality medicines to approximately 1 billion patients annually Report chronicles Viatris' commitment to providing access to healthcare and building healthier communities Impactful story highlights include "Empathy in Africa: Bridging the Healthcare Divide" – a powerful new documentary short that showcases Viatris' impact PITTSBURGH, May 21, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2023 Sustainability Report: Building ...

Viatris Inc. (NASDAQ:VTRS) BofA Securities 2024 Health Care Conference May 14, 2024 1:00 PM ET Company Participants Doretta Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Jason Gerber - BoA Securities Jason Gerber All right, everybody, we're going to get going here with our next company presenter at the Bank Of America Annual Healthcare Conference. We got Viatris. And joined with us is CFO, Doretta Mistras, and Philippe Martin, Chief R&D Officer. So thank ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

Viatris Inc. (VTRS) delivered adjusted earnings of 67 cents per share in the first quarter of 2024, missing the Zacks Consensus Estimate by a penny. The company recorded adjusted earnings of 77 cents in the year-ago quarter.Total revenues came in at $3.66 billion, down 1.7% year over year. Revenues include product sales and other revenues. The top line missed the Zacks Consensus Estimate of $3.7 million.Viatris’ stock is trading down in response to the first-quarter results mainly due to a miss on both earn ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2024 was approximately $3.7 billion, with adjusted EBITDA of approximately $1.2 billion and adjusted EPS of $0.67 per share [9][18] - Free cash flow for the quarter was approximately $565 million, with an adjusted gross margin of approximately 59% [9][24] - The company reaffirmed its 2024 financial guidance, including a new product revenue range of $450 million to $550 million [10][27] Business Line Data and Key Metrics Changes - The North America business declined approximately 3% year-over-year, impacted by formulary changes and channel dynamics, while emerging markets delivered approximately 9% year-over-year operational growth [21][22] - New product revenue was better than expected at $154 million for the quarter, driven by strong performance in products like Yupelri and Tyrvaya [20][21] - The eye care pipeline includes the launch of Ryzumvi in the US and ongoing Phase 3 studies for MR-139 and MR-142 [15][16] Market Data and Key Metrics Changes - Developed markets in Europe grew approximately 2% year-over-year, while JANZ grew approximately 2% due to business expansion in Australia [21][23] - Greater China results were flat compared to Q1 2023, with a focus on the retail segment and self-paid patient base [23] Company Strategy and Development Direction - The company is focused on maintaining base business stability while driving new product revenue and making strategic investments for future growth [6][11] - Recent transactions, including the divestiture of the women's healthcare business and the acquisition of Idorsia, are part of the strategy to enhance the product portfolio and drive innovation [7][19] - The leadership team has been strengthened with new appointments to support the company's growth objectives [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet its financial guidance for 2024, despite challenges in certain markets [27][28] - The company anticipates modest revenue growth in the second half of the year, driven by normal product seasonality and strong uptake of new products [28] Other Important Information - The company returned $393 million to shareholders in Q1 through dividends and share buybacks, with a declared quarterly dividend of $0.12 per share [11][26] - The company ended the quarter with approximately $1 billion in cash and cash equivalents [26] Q&A Session Summary Question: North America softness in brands and GA Depot timeline - Management noted that North America was impacted by formulary changes and channel dynamics, with expectations for offsetting growth in other brands [30][31] - The timeline for GA Depot approval will be clarified after an upcoming meeting with the FDA [33] Question: Tyrvaya growth and free cash flow expectations - Management is optimistic about Tyrvaya's growth trajectory and reaffirmed confidence in achieving $450 million to $550 million in new product revenue [36][37] Question: API and OTC divestiture timelines - The API divestiture is expected to close imminently, while the OTC divestiture is anticipated to close by mid-year, subject to regulatory approvals [39] Question: JANZ business dynamics and new product revenue - JANZ is performing as expected, with growth driven by business activities in Australia, and management is confident in achieving new product revenue guidance [41][43] Question: Idorsia assets and capital deployment strategy - The expansion of site enrollment for Idorsia assets is not reflected in previously presented timelines, and management is exploring various capital deployment opportunities, including share buybacks [46][49] Question: Complex injectables and future launches - The complex injectable portfolio is a priority for the company, with significant ongoing investments and a robust pipeline of products under FDA review [51][53] Question: Sustainability of emerging markets performance - Emerging markets showed strong performance, and management is pleased with the results despite some FX headwinds [56]

For the quarter ended March 2024, Viatris (VTRS) reported revenue of $3.66 billion, down 1.8% over the same period last year. EPS came in at $0.67, compared to $0.78 in the year-ago quarter. The reported revenue represents a surprise of -2.12% over the Zacks Consensus Estimate of $3.74 billion. With the consensus EPS estimate being $0.68, the EPS surprise was -1.47%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Viatris (VTRS) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.47%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.67 per share when it actually produced earnings of $0.61, delivering a surprise of -8.96%.Over the last four quarters, the compan ...

Lara Ramsburg Chief Corporate Affairs Officer Brian Roman Chief Legal Officer Q1 2024 Select Key Product Net Sales, on a Consolidated Basis 22 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2024 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Full-Year 2024 Guidance Items as of May 9, 2024(1) | --- | --- | |--------------------- ...

• Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million; and Free Cash Flow of $565 Million for the First Quarter • Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1] • Reaffirms 2024 New Product Revenue Range of $450 Million to $550 Million • Closes Idorsia Transaction, Expanding Por ...

Investors are always looking for stocks that are poised to beat at earnings season and Viatris Inc. (VTRS) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Viatris is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicato ...